GSK Raises Annual Forecasts Despite Weak Vaccine Sales and Outlook
GSK raises 2024 earnings and sales forecasts after strong Q2 performance, driven by cancer and HIV treatments. However, weak vaccine sales, including the new RSV vaccine Arexvy, weigh on shares. Bollywood Fever: British drugmaker...
